Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

NCT06282458 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT06282458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management
Lead sponsor
Veru Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2024
Completion date
August 22, 2025
Enrollment
168 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

muscle loss, obesity